(Q33910607)

30 July 2017

1 reference

title

Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support (English)

1 reference

30 July 2017

1 reference

Labrie F

1

1 reference

30 July 2017

1 May 2000

1 reference

30 July 2017

1 reference

30 July 2017

43

1 reference

30 July 2017

215-222

1 reference

30 July 2017

3

1 reference

30 July 2017

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Influence of benign prostatic hyperplasia, testosterone and age on serum levels of prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Population-based study of long-term survival in patients with clinically localised prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Cancer incidence and mortality, 1973-1995: a report card for the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Downward trend in prostate cancer mortality in Quebec and Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Expectant management of localized prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Age, and size and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Deferred treatment in clinically localised prostatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Results of conservative management of clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Natural history of localised prostatic cancer managed by conservative therapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Prostate adenocarcinoma in men younger than 50 years. A retrospective review of 151 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Prostate cancer consensus hampered by lack of data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Prostate cancer mortality in patients surviving more than 10 years after diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Cancer mortality rates fall: a turning point for the nation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Prospective, conservative management of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Cancer of the prostate: is there a need for aggressive treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Origin and development of carcinoma in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Long-term followup results after expectant management of stage A1 prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

The national survey of prostate cancer in the United States by the American College of Surgeons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000515%2943%3A3%3C215%3A%3AAID-PROS7%3E3.0.CO%3B2-G

10.1002/(SICI)1097-0045(20000515)43:3<215::AID-PROS7>3.0.CO;2-G

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10797496